Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 7/20 | 0.32 |
| ▸ | CCL2 | P13500 | 5/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657157 | 0.82 | BRD4 (0.35) | BRD4CCL2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23356597 | 0.81 | BRD4 (0.46) | BRD4CCL2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23356619 | 0.75 | ACP3 (0.40) | LMNABRD4 | |
| SCHEMBL28089132 | 0.72 | BRD4 (0.33) | BRD4CCL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28263462 | 0.66 | ALDH1A1 (0.39) | LMNABRD4CCL2 | |
| SCHEMBL23356557 | 0.65 | TDP1 (0.36) | TSHRL3MBTL1 | |
| SCHEMBL29657202 | 0.62 | BRD4 (0.44) | BRD4CCL2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23356612 | 0.61 | — | — | |
| P-Xylene SCHEMBL28910761 | 0.60 | LMNA (0.68) | LMNATSHRCYP3A4 | |
| P-Xylene SCHEMBL27900454 | 0.60 | LMNA (0.68) | LMNATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | CBR1, POR, CAT | LMNA 1379/4885TSHR 4242/4885BRD4 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.